{"database": "openregs", "table": "documents", "rows": [["FDA-2011-D-0611-0094", "FDA", "FDA-2011-D-0611", "New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) Guidance for Industry - \nDraft Guidance", "Other", "Guidance", "2026-03-10T04:00:00Z", 2026, 3, "2026-03-10T04:00:00Z", "2026-05-12T03:59:59Z", "2026-05-12T09:00:11Z", null, 1, 0, "09000064b92071bb"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2011-D-0611-0094"], "units": {}, "query_ms": 1.6525459941476583, "source": "U.S. government sources, plus a few identifier registries; each is listed on the methodology page", "source_url": "https://datadawn.org/methodology#data", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}